Atjaunināt sīkdatņu piekrišanu

E-grāmata: Mechanism of Artificial Heart

  • Formāts: PDF+DRM
  • Izdošanas datums: 19-Feb-2016
  • Izdevniecība: Springer Verlag, Japan
  • Valoda: eng
  • ISBN-13: 9784431558316
  • Formāts - PDF+DRM
  • Cena: 142,16 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: PDF+DRM
  • Izdošanas datums: 19-Feb-2016
  • Izdevniecība: Springer Verlag, Japan
  • Valoda: eng
  • ISBN-13: 9784431558316

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This book first describes medical devices in relation to regenerative medicine before turning to a more specific topic: artificial heart technologies. Not only the pump mechanisms but also the bearing, motor mechanisms, and materials are described, including expert information. Design methods are described to enhance hemocompatibility: main concerns are reduction of blood cell damage and protein break, as well as prevention of blood clotting. Regulatory science from R&D to clinical trials is also discussed to verify the safety and efficacy of the devices.
1 Introduction
1(2)
2 What Kinds of Artificial Hearts Are Available?
3(10)
2.1 Population of Heart Patients
3(1)
2.2 Total-Replacement Artificial Hearts and Ventricular Assist Devices
3(1)
2.3 Generation Progress of Implantable Ventricular Assist Devices
4(3)
2.4 Practical Artificial Hearts: 1st to 3rd Generation
7(6)
References
12(1)
3 How Do We Select Pump Types?
13(10)
3.1 Pulsatile Flow Pumps (Reciprocating Pumps and Rotary Displacement Pumps)
13(1)
3.2 Continuous Flow Pumps (Rotary Pumps or Turbo Pumps)
13(10)
3.2.1 Pump Output
16(2)
3.2.2 Volute and Diffuser
18(1)
3.2.3 Force Balance of a Centrifugal Impeller
19(1)
3.2.4 Open, Semi-Open, and Closed Type Impellers
20(1)
3.2.5 Force Balance of an Axial-Flow Impeller
20(1)
References
21(2)
4 Selection of Bearing Types: A Key to Durability
23(10)
4.1 Pivot Bearing
23(1)
4.2 Magnetic Bearing and Hydrodynamic Bearing
23(3)
4.3 Analysis of Hydrodynamic Bearing
26(7)
References
31(2)
5 Motor, Battery, and Magnetic Suspension
33(4)
5.1 Motor Mechanism
33(1)
5.2 Battery and Cable
33(1)
5.3 Magnetic Suspension
34(3)
Reference
35(2)
6 Flow Visualization and Computational Fluid Dynamic Analysis
37(14)
6.1 Particle Image Velocimetry (PIV)
37(8)
6.1.1 Visualization of a Centrifugal Blood Pump
37(4)
6.1.2 Visualization Regarding Washout Hole Flow
41(1)
6.1.3 Visualization of a Gap Flow in a Centrifugal Blood Pump
42(3)
6.2 Computational Fluid Dynamic (CFD) Analysis
45(2)
6.3 Similarity Laws: Development Tool
47(4)
6.3.1 Similarity Law 1: Reynolds Number
47(1)
6.3.2 Similarity Law 2: Specific Speed
47(1)
6.3.3 Meaning of the Variation of the Two Similarity Parameters for a Pump
48(1)
References
49(2)
7 How Do We Select Materials?
51(6)
7.1 Pump Material
51(1)
7.2 Coating Material
51(1)
7.3 Bearing Material
52(2)
7.4 Durability Testing
54(3)
References
55(2)
8 Enhancement of Hemocompatibility
57(12)
8.1 What Kinds of Hemocompatibility Should be Considered
57(1)
8.2 What Is Hemolysis and Its Criterion
57(2)
8.3 What Is Thrombus Formation and Its Criterion
59(1)
8.4 What Is vWF Damage
60(1)
8.5 Testing Methods
61(8)
8.5.1 In Vitro Hemolysis Testing
61(2)
8.5.2 In Vitro Anti-throbogenicity Testing
63(1)
8.5.3 Animal Testing (In Vivo Evaluation)
64(2)
References
66(3)
9 System Evaluation
69(8)
9.1 Clinical Trial
69(1)
9.2 Regulatory Science
70(7)
9.2.1 Standard and Guidance
70(5)
References
75(2)
10 Remarks and Future Aspect
77